FDA Approved JUUL2 for Two Flavors. Crème Brûlée Odds Jumped to 24%.

---

JUUL Got FDA Approval, But Only for Two Flavors. Here's What That Means for Crème Brûlée in 2026.

JUUL is not bringing back Crème Brûlée pods right now. The FDA's August 28 authorization of the JUUL2 system covered exactly three products: the device itself, a tobacco-flavored pod, and a menthol-flavored pod. No dessert flavors. No fruit flavors. No Crème Brûlée. Yet on prediction markets, the implied probability that JUUL relaunches Crème Brûlée before December 31, 2026 has jumped from 11% to 24% in three days.

The catalyst is not what the FDA approved. It's what JUUL's CEO said next. K.C. Crosthwaite publicly stated plans to seek authorization for a broader flavor range targeting adult nicotine consumers, according to CBS News. That single statement transformed a narrow regulatory win into a speculative runway for every flavor JUUL ever discontinued.

Traders are not pricing a product. They are pricing a promise, backed by the first positive FDA signal JUUL has received in over a decade.

---

Crème Brûlée Odds Nearly Doubled After JUUL's FDA Win. Here's the Live Market.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Crème Brûlée

Consensus YES price across 2 venues

9%average

KalshiBest YES price9¢Polymarket28¢

Mint

Consensus YES price across 1 venues

15%average

KalshiBest YES price16¢

Mango

Consensus YES price across 1 venues

6%average

KalshiBest YES price9¢

Cucumber

Consensus YES price across 1 venues

1%average

KalshiBest YES price9¢

Current new-user offer · Kalshi

Get a $35 trading bonusCode PRED35

New users only. Eligibility restrictions and terms apply.

View current offer

The 13-percentage-point move in Crème Brûlée contracts since August 28 reflects a specific kind of market behavior: gap pricing. The FDA answered the binary question of whether JUUL could sell any product at all. Crosthwaite's statement opened a second question about which flavors come next. Traders are filling the space between those two data points with speculative capital.

On Kalshi, Crème Brûlée trades at 26%. On Polymarket, the same outcome sits at 22%. That 4-percentage-point spread suggests both platforms are responding to the same information, with Kalshi's regulated user base pricing slightly more confidence in JUUL's ability to navigate the FDA pipeline by year-end.

The period low for this contract was 9%. The move to 24% represents a 15-percentage-point swing from the floor, nearly all of it concentrated in the 72 hours following the JUUL2 authorization. This is not a gradual repricing. It is a step-function response to a regulatory event that changed the probability picture for every flavor in the market.

What makes the Crème Brûlée move distinctive is the absence of any flavor-specific news. No leaked documents. No supply chain signals. No retailer listings. The entire move derives from the CEO's forward-looking statement applied to a catalog of discontinued flavors. Within the "What flavors will JUUL relaunch?" market, Crème Brûlée sits as one of several outcomes where traders are essentially placing bets on Crosthwaite's execution speed.

---

Why Did JUUL Discontinue Crème Brûlée? The Regulatory History Traders Are Betting Against

JUUL voluntarily pulled Crème Brûlée, along with Mango, Fruit Medley, Cucumber, and other flavored pods from U.S. retail in late 2019. The withdrawal came under intense FDA pressure tied to the youth vaping crisis. JUUL did not wait for a formal ban. It preemptively removed the products as part of a strategy to preserve its core tobacco and menthol business while regulators developed the premarket tobacco product application (PMTA) framework.

That framework is the structural barrier traders are now betting against. Each flavor requires its own PMTA submission, its own scientific review, and its own authorization. The FDA's review of the JUUL2 tobacco and menthol pods considered data showing that 19.9% to 34.6% of tobacco-pod users and 28.4% to 49.3% of menthol-pod users stopped smoking cigarettes entirely at six weeks, according to the FDA's authorization summary. Any Crème Brûlée submission would need to clear the same population-health standard: demonstrating that the benefits of adult switching outweigh the risks of youth uptake.

Dessert flavors face a harder version of that argument. Menthol succeeded partly because its switching data was strong. A Crème Brûlée pod would need to prove it also drives meaningful cessation from combustible cigarettes, while simultaneously convincing the FDA that a dessert flavor does not disproportionately attract minors. That is a taller order, and JUUL has not publicly disclosed whether it has even submitted a PMTA for Crème Brûlée.

---

The Strongest Case Against Crème Brûlée: Why 24% May Be Too High

Four months remain before this market resolves on December 31, 2026. For Crème Brûlée to pay out, JUUL would need to submit a PMTA (if it hasn't already), have the FDA complete its scientific review, receive authorization, and relaunch the product, all before the calendar turns.

Consider the timeline of what just happened. The JUUL2 device and its two authorized flavors went through a review process that took years. The FDA does not fast-track flavor applications because a CEO expressed interest in expanding a portfolio. Crosthwaite's statement was strategic positioning, not a regulatory filing.

There is also the political dimension. The FDA's authorization of JUUL2 already drew scrutiny from public health advocates concerned about youth access. Adding a dessert-flavored pod to the market would amplify that scrutiny considerably. The JUUL2 system includes age-verification technology, as AP News reported, which could theoretically ease some FDA concerns. But age-gating hardware does not change the regulatory standard for flavor authorization.

The honest reading of 24% is that roughly three-quarters of the market believes Crème Brûlée will not return this year. The minority position is that JUUL has been quietly advancing multiple flavor PMTAs behind the scenes, and the August 28 authorization was simply the first domino. Without evidence of a pending application, 24% prices a lot of optimism into a very compressed timeline.

---

What Resolves This Market, and What to Watch

This contract expires December 31, 2026. Resolution requires JUUL to actually relaunch Crème Brûlée pods for sale in the U.S., not merely announce plans or file paperwork. The gap between intention and execution is where most of the risk sits.

Three developments would move the price meaningfully before resolution. First, any leak or announcement of a PMTA submission for flavored pods beyond tobacco and menthol. Second, FDA guidance or public statements about the timeline for reviewing additional JUUL flavor applications. Third, retailer or distributor activity suggesting imminent product availability.

For readers tracking this and other outcomes in the broader event, live prices across all flavor candidates are available on the What flavors will JUUL relaunch? odds page.

At 24%, Crème Brûlée is priced as a plausible but unlikely relaunch within four months. The market is not irrational. It is placing a specific, bounded bet that Crosthwaite's public ambition has regulatory substance behind it. Whether that substance exists is, as of today, entirely unverified.